The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells
about
Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Clinical implications of basic research in hepatocellular carcinoma.NMI inhibits cancer stem cell traits by downregulating hTERT in breast cancer.Oligonucleotides Targeting Telomeres and Telomerase in Cancer
P2860
The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@ast
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@en
type
label
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@ast
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@en
prefLabel
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@ast
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@en
P2860
P1476
The telomerase inhibitor imete ...... l of HER2+ breast cancer cells
@en
P2093
Jillian E Koziel
P2860
P2888
P304
P356
10.1007/S10549-015-3270-1
P407
P577
2015-01-28T00:00:00Z